Clinical trials
Cancer (With or Without Metastasis) clinical trials
Below are recruiting cancer (with or without metastasis) clinical trials, each written for real people, not researchers. We’re tracking 13,086 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05528237Enrolling by invitation
HPV self-test to help cervical cancer screening access
This trial studies whether letting people collect their own HPV test sample (a private, at-home option) makes cervical cancer screening easier for people with HIV and/or those who are often underserved. If you’ve declined a Pap test or it’s been 6+ months since your last screening, this may offer a more convenient way to check for HPV and cervical cancer risk.
Seattle, WashingtonAges 25 years+ - NCT05544084Recruiting
Patient navigation program for cervical screening in Senegal
This study tests a patient “navigator” approach to improve cervical cancer screening and prevention access in Senegal. You may be invited to help through community education, health facility work, or by being part of a screening-support household.
DakarAges 25–69 - NCT05534087RecruitingPhase 3
Blood test guided chemo after colon cancer surgery
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
BusanAges 19–75 - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT04696575RecruitingPhase 2
Lamivudine added to chemoimmunotherapy for extensive-stage lung cancer
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
Buffalo, New YorkAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Beverly Hills, CaliforniaAges 8 years+ - NCT05470348RecruitingPhase 1
Test drug BL-B01D1 for advanced breast and other solid cancers
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Guangzhou, GuangdongAges 18–75 - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05482568RecruitingPhase 1/Phase 2
Study drug SHR-A1811 with two lung cancer medicines
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04214119Recruiting
Capsule test during endoscopy to find early esophageal cancer
This trial studies an “EsophaCap” capsule that can be swallowed during an endoscopy to help detect early esophageal cancer. It may help find cancer earlier and guide next steps, if your results are concerning.
Baltimore, MarylandAges 18 years+ - NCT05391126Recruiting
Genetic test helps choose drug dosing for pancreas or colon cancer
This study tests whether using a genetic test to guide medication doses works better than standard dosing for people with certain pancreas or colon cancers. It may help by tailoring treatment more precisely to your tumor’s genetic features.
Lexington, KentuckyAges 18 years+ - NCT05389332Recruiting
Mobile WhatsApp program to help reduce skin cancer risk
This trial tests a mobile phone health program (using WhatsApp) to help Hispanic adults lower their risk of skin cancer. It focuses on encouraging better sun protection and checking your skin regularly.
New Brunswick, New JerseyAges 18–100 - NCT05472792RecruitingPhase 2
Testing breast radiation after lumpectomy with or without hormone pills
This Phase 2 trial compares different “after-surgery” treatment plans for certain older women with hormone-sensitive early breast cancer. It looks at whether a standard hormone-pills approach or a faster, smaller-area radiation approach (given after lumpectomy) works best to prevent cancer coming back.
Chapel Hill, North CarolinaAges 65 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05483283Recruiting
Latina women study to help access breast cancer care
This trial supports Latina women who have higher breast cancer risk and face added barriers (like cost, transportation, safety, or isolation) to get recommended breast screening and genetic risk information. It aims to help you understand your risk and access care when it’s due.
Chicago, IllinoisAges 30 years+ - NCT05481697Recruiting
Track weight changes and check with a cancer blood test
This study looks at whether closely tracking small, unplanned weight loss—along with a one-time blood test (Galleri)—can help find cancer earlier. It may help people who notice changes in weight without knowing why.
Cleveland, OhioAges 40–80 - NCT05492136Recruiting
Radiofrequency during liver surgery to reduce cancer coming back
This study looks at whether using radiofrequency (a heat-based treatment used during surgery) during liver surgery can lower the chances that cancer returns locally. It includes people with colorectal cancer that has spread to the liver and people with liver cancer (HCC).
BarcelonaAges 18 years+ - NCT05491226RecruitingPhase 2
Pembrolizumab plus radiation and myeloid-targeting for high-risk breast cancer
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
Los Angeles, CaliforniaAges 18 years+ - NCT05478694Recruiting
Focal ablation outcomes for prostate cancer
This study looks at how well a targeted procedure (“focal ablation,” which destroys only the cancer area) works for certain men with prostate cancer that is limited to the prostate. It may help doctors understand which people benefit most and what outcomes to expect.
Dallas, TexasAges 18–90 - NCT05450965RecruitingPhase 2
Onvansertib for relapsed small cell lung cancer
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Baltimore, MarylandAges 18 years+ - NCT05255003RecruitingPhase 4
Anticoagulation options for low platelets with cancer blood clots
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Edmonton, AlbertaAges 18 years+ - NCT05445791RecruitingPhase 3
Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Mexico CityAges 18 years+ - NCT05415007Recruiting
Support program for parents and teens after a new cancer diagnosis
This study tests a brief program meant to reduce anxiety and build resilience in families when a child was newly diagnosed with cancer. It involves both the parent and the child (ages 8–17) and requires consent/assent and English ability.
San Francisco, CaliforniaAges 8–18
Hear when a new Cancer (With or Without Metastasis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer (with or without metastasis)?
- Yes. Clin2 currently lists 13,086 recruiting cancer (with or without metastasis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer (with or without metastasis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer (with or without metastasis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Liver Metastasis Colon Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Colorectal Cancer Liver Metastasis
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Leptomeningeal Metastasis of Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.